John Laterra
Affiliations: | Johns Hopkins University, Baltimore, MD |
Area:
Neuroscience BiologyGoogle:
"John Laterra"Mean distance: 53433
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ko M, Makena MR, Schiapparelli P, et al. (2022) The endosomal pH regulator NHE9 is a driver of stemness in glioblastoma. Pnas Nexus. 1: pgac013 |
| Lopez-Bertoni H, Johnson A, Rui Y, et al. (2022) Sox2 induces glioblastoma cell stemness and tumor propagation by repressing TET2 and deregulating 5hmC and 5mC DNA modifications. Signal Transduction and Targeted Therapy. 7: 37 |
| Zhan D, Yalcin F, Ma D, et al. (2021) Targeting UDP-α-d-glucose 6-dehydrogenase alters the CNS tumor immune microenvironment and inhibits glioblastoma growth. Genes & Diseases. 9: 717-730 |
| Zhan D, Ma D, Wei S, et al. (2021) Monoallelic IDH1 R132H mutation mediates glioma cell response to anti-cancer therapies via induction of senescence. Molecular Cancer Research : McR |
| Ma D, Zhan D, Fu Y, et al. (2021) Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1. Cancer Letters |
| Laterra J, Ma T, Hu C, et al. (2021) Reprogramming transcription factors Oct4 and Sox2 induces a BRD-dependent immunosuppressive transcriptome in GBM-propagating cells. Cancer Research |
| de la Rocha AMA, González-Huarriz M, Guruceaga E, et al. (2020) miR-425-5p, a SOX2 target, regulates the expression of FOXJ3 and RAB31 and promotes the survival of GSCs. Archives of Clinical and Biomedical Research. 4: 221-238 |
| Thummalapalli R, Heumann T, Stein J, et al. (2020) Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma. Case Reports in Oncology. 13: 508-514 |
| Lopez-Bertoni H, Kotchetkov IS, Mihelson N, et al. (2020) A Sox2/miR-486-5p axis regulates survival of GBM cells by inhibiting tumor suppressor networks. Cancer Research |
| Xu Q, Hu C, Zhu Y, et al. (2020) ShRNA-based POLD2 expression knockdown Sensitizes Glioblastoma to DNA-Damaging Therapeutics. Cancer Letters |